Unlike hGH, which carries broader systemic effects and risks associated with elevated IGF-1 levels, AOD9604 appears to selectively promote fat metabolism without triggering growth-related side effects, suggesting its potential as a safer therapeutic candidate for obesity and metabolic disorders [2]
It is best understood as a possible adjunct to diet and exercise, not a standalone weight loss solution
AOD9604 interacts selectively with metabolic pathways associated with the C-terminal domain, making it a more targeted research tool for lipolytic pathway studies without the confounding variables of full hGH activity
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
doi: 10.1126/science.194.4269.1027
Unlike other peptides, which primarily work through appetite suppression and metabolic regulation, these peptides go deeper, supporting mitochondrial function, enhancing fat oxidation, increasing muscle protein synthesis, and even reversing aspects of cellular aging